JP2012511033A - 多価化合物の可逆阻害用マスキングリガンド - Google Patents

多価化合物の可逆阻害用マスキングリガンド Download PDF

Info

Publication number
JP2012511033A
JP2012511033A JP2011539791A JP2011539791A JP2012511033A JP 2012511033 A JP2012511033 A JP 2012511033A JP 2011539791 A JP2011539791 A JP 2011539791A JP 2011539791 A JP2011539791 A JP 2011539791A JP 2012511033 A JP2012511033 A JP 2012511033A
Authority
JP
Japan
Prior art keywords
antibody
masking
epitope
ligand
masking ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511033A5 (https=
Inventor
ウィリアムズ，ジョン
ロデック，ウルリッヒ
Original Assignee
テゴファーム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テゴファーム コーポレーション filed Critical テゴファーム コーポレーション
Publication of JP2012511033A publication Critical patent/JP2012511033A/ja
Publication of JP2012511033A5 publication Critical patent/JP2012511033A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011539791A 2008-12-08 2009-12-08 多価化合物の可逆阻害用マスキングリガンド Pending JP2012511033A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12065708P 2008-12-08 2008-12-08
US61/120,657 2008-12-08
US14761109P 2009-01-27 2009-01-27
US61/147,611 2009-01-27
PCT/US2009/067119 WO2010077643A1 (en) 2008-12-08 2009-12-08 Masking ligands for reversible inhibition of multivalent compounds

Publications (2)

Publication Number Publication Date
JP2012511033A true JP2012511033A (ja) 2012-05-17
JP2012511033A5 JP2012511033A5 (https=) 2013-02-14

Family

ID=42310107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011539791A Pending JP2012511033A (ja) 2008-12-08 2009-12-08 多価化合物の可逆阻害用マスキングリガンド

Country Status (4)

Country Link
US (1) US20100189727A1 (https=)
EP (1) EP2356131A4 (https=)
JP (1) JP2012511033A (https=)
WO (1) WO2010077643A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520614A (ja) * 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
JP2016538240A (ja) * 2013-09-25 2016-12-08 シトムクス セラピューティクス，インコーポレイティド マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
JP2018509182A (ja) * 2015-03-13 2018-04-05 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2018520642A (ja) * 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
JP2020098195A (ja) * 2013-01-04 2020-06-25 シトムクス セラピューティクス，インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
JP2022065174A (ja) * 2013-07-25 2022-04-26 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
CN103561771B (zh) * 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
WO2017120589A1 (en) * 2016-01-08 2017-07-13 Washington University Compositions comprising chemerin and methods of use thereof
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
BR112019011564A2 (pt) 2016-12-09 2019-10-22 Seattle Genetics Inc anticorpos bivalentes mascarados por hélices superenroladas
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
US11939385B2 (en) * 2017-05-16 2024-03-26 ALX Oncology Inc. Activatable antibodies and methods of use thereof
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
JP2020531430A (ja) 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗体を標的とする抗ｃｔｌａ４プロボディ療法
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
EP3735254A4 (en) * 2018-01-05 2021-11-03 City of Hope MULTI-SPECIFIC LIGAND BINDERS
IL325995A (en) 2018-02-08 2026-03-01 Genentech Inc Bispecific antigen binding molecules and methods of use
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN113316590B (zh) 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
CN113924118A (zh) 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
CN115485302A (zh) 2020-03-09 2022-12-16 百时美施贵宝公司 具有增强的激动剂活性的针对cd40的抗体
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2024113099A1 (en) * 2022-11-28 2024-06-06 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable recombinant bispecific antibodies and compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185281A (ja) * 2003-12-04 2005-07-14 Mbl Venture Capital Co Ltd 細胞表面抗原に対する抗体取得とその抗原同定
JP2005536987A (ja) * 2002-04-01 2005-12-08 ユーロ−セルティーク エス．エイ． 抗原提示細胞標的化機構を含むエピトープ構築物
JP2007524105A (ja) * 2004-02-25 2007-08-23 バイオエンハンスメンツ リミテッド 結合物質
JP2007527225A (ja) * 2003-07-30 2007-09-27 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｅｐｈａ２ｔ−細胞エピトープアゴニストおよびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306731A (en) * 1985-06-14 1994-04-26 Massachusetts Eye And Ear Infirmary Method and products for treating the eye
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US5861160A (en) * 1995-06-07 1999-01-19 Ambico, Inc. Isospora suis sporozoite antigen
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
US20030134824A1 (en) * 2001-11-12 2003-07-17 Ronald Breslow Beta-cyclodextrin dimers and phthalocyanines and uses thereof
US6680236B2 (en) * 2002-01-11 2004-01-20 Raytheon Company Ion-implantation and shallow etching to produce effective edge termination in high-voltage heterojunction bipolar transistors
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
JP4351430B2 (ja) * 2002-10-04 2009-10-28 財団法人癌研究会 ナノ黒鉛構造体に結合能を有するペプチド
CN1548537B (zh) * 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
US7338432B2 (en) * 2003-11-17 2008-03-04 Konstantin Valtchev Urethral sling introducer and method of use
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
WO2006090813A1 (ja) * 2005-02-25 2006-08-31 National University Corporation Hokkaido University 腫瘍組織で選択的に分解性を示す血中滞留性素子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536987A (ja) * 2002-04-01 2005-12-08 ユーロ−セルティーク エス．エイ． 抗原提示細胞標的化機構を含むエピトープ構築物
JP2007527225A (ja) * 2003-07-30 2007-09-27 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｅｐｈａ２ｔ−細胞エピトープアゴニストおよびその使用
JP2005185281A (ja) * 2003-12-04 2005-07-14 Mbl Venture Capital Co Ltd 細胞表面抗原に対する抗体取得とその抗原同定
JP2007524105A (ja) * 2004-02-25 2007-08-23 バイオエンハンスメンツ リミテッド 結合物質

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020098195A (ja) * 2013-01-04 2020-06-25 シトムクス セラピューティクス，インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
JP7001652B2 (ja) 2013-01-04 2022-02-21 シトムクス セラピューティクス，インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
JP2016520614A (ja) * 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
JP2022065174A (ja) * 2013-07-25 2022-04-26 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
JP2016538240A (ja) * 2013-09-25 2016-12-08 シトムクス セラピューティクス，インコーポレイティド マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
JP2018509182A (ja) * 2015-03-13 2018-04-05 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2021072807A (ja) * 2015-03-13 2021-05-13 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
US11174316B2 (en) 2015-03-13 2021-11-16 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP7165217B2 (ja) 2015-03-13 2022-11-02 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2018520642A (ja) * 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
WO2010077643A1 (en) 2010-07-08
US20100189727A1 (en) 2010-07-29
EP2356131A1 (en) 2011-08-17
EP2356131A4 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
JP2012511033A (ja) 多価化合物の可逆阻害用マスキングリガンド
JP7819160B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
AU2023254931B2 (en) Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
JP7412521B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
AU2019394972B2 (en) Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP6571730B2 (ja) 改変した抗体組成物、それを作製および使用する方法
CN107531758A (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
BR112020004543A2 (pt) proteínas de ligação ativadas condicionalmente restritas
KR20180002734A (ko) IgG 결합 펩타이드에 의한 항체의 특이적 변형
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
US20250188172A1 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2023143547A1 (zh) 抗cd28抗体及其应用
EP4240407A1 (en) Antigen binding domain with reduced clipping rate
US20240360195A1 (en) Novel fab dimers
TW202540163A (zh) 利用環境應答性胜肽的蛋白質之製造方法
HK40023271A (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
NZ755670A (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20120727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141021